BLADDER UROTHELIAL CARCINOMA
Clinical trials for BLADDER UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BLADDER UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for BLADDER UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Bladder-Sparing cancer combo aims to boost cure rates
Disease control OngoingThis study is testing whether adding a drug called durvalumab (an immunotherapy) to standard chemotherapy and radiation works better for treating bladder cancer that has spread to nearby lymph nodes. The main goal is to see if more patients achieve a complete response, meaning no…
Matched conditions: BLADDER UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 06:05 UTC
-
Major trial aims to boost bladder cancer survival with Immune-Boosting drug
Disease control OngoingThis large, late-stage trial is testing whether adding an immunotherapy drug (atezolizumab) to the standard treatment of chemotherapy and radiation improves results for patients with muscle-invasive bladder cancer. The goal is to better control the cancer and help patients keep t…
Matched conditions: BLADDER UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Scientists test Triple-Threat drug combo against Tough-to-Treat cancers
Disease control OngoingThis early-stage study is testing the safety and best doses of a combination of cancer drugs for people with advanced cancers of the urinary system (like bladder and kidney cancer) that have spread. The trial combines a pill (cabozantinib) that aims to block tumor growth with one…
Matched conditions: BLADDER UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Targeted drug combo tested to fight tough bladder cancer
Disease control TerminatedThis study aimed to see if a targeted pill (erdafitinib) alone or combined with an immunotherapy drug (atezolizumab) could shrink aggressive bladder tumors before surgery. It was for patients whose cancer had grown into the muscle wall of the bladder and who could not receive the…
Matched conditions: BLADDER UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC